Category Archives: Business of Biotech

Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that dosing has begun in a Phase II trial of ANA598 in patients chronically infected with hepatitis C virus (HCV). The study will evaluate ANA598 over 12 weeks, taken in combination with pegylated interferon-alpha and ribavirin, in treatment naïve HCV patients. ANA598 is an investigational, oral, nonnucleoside polymerase inhibitor. Anadys has completed three Phase I clinical studies of ANA598 that have demonstrated potent antiviral activity and good tolerability. Read More >

XOMA Ltd. (Nasdaq:XOMA) and Arana Therapeutics Limited, a wholly-owned subsidiary of Cephalon, Inc. (Nasdaq:CEPH) will collaborate on multiple proprietary XOMA antibody R&D technologies, including a new antibody phage display library, and a suite of integrated information and data management systems. Arana will pay XOMA a fee of $6 million and XOMA will receive milestone payments and royalties on product sales. The proprietary antibody library covered by the collaboration is one of a series of proprietary Read More >

An interview with Dr. Peter A. Thompson, MD, FACP, President, CEO, & Chairman of the Board of Directors of Trubion Pharmaceuticals: What is one aspect of your company that you feel would be most attractive or exciting to investors? We currently have three product candidates in the clinic with two, strategic collaborations underlying their development – Wyeth for our CD20 programs and Facet for our CD37 programs. Data disclosures later this year from key clinical trials Read More >

Forbes’ Jonathan Fahey wrote an excellent article on influenza and the H1N1 virus this morning. The article is significant for a couple reasons. First, he captures the overall situation so just in case you haven’t read a story or heard about H1N1 yet (and have been living under a rock), you get the full picture quickly and succinctly. Even if you have read about it, it’s always nice to get a quick recap just to Read More >